Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners

The treatment of cancer patients with immune checkpoint inhibitors (ICI) (anti-CTLA-4, anti-PD-1, anti-PD-L1, combined therapy anti-PD-1/PD-L1 with anti-CTLA-4) has without doubt been a significant breakthrough in the field of oncology in recent years and constitutes a major step forward as a novel...

Descripción completa

Detalles Bibliográficos
Autores principales: Wojtukiewicz, Marek Z., Rek, Magdalena M., Karpowicz, Kamil, Górska, Maria, Polityńska, Barbara, Wojtukiewicz, Anna M., Moniuszko, Marcin, Radziwon, Piotr, Tucker, Stephanie C., Honn, Kenneth V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556173/
https://www.ncbi.nlm.nih.gov/pubmed/34236546
http://dx.doi.org/10.1007/s10555-021-09976-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556173/
https://www.ncbi.nlm.nih.gov/pubmed/34236546
http://dx.doi.org/10.1007/s10555-021-09976-0

Ejemplares similares